Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Balu

Showing results (11-20 of 76) with videos related to

Pageof 8
Sort By:
Communications Medicine|December 8, 2023
A mechanistic marker-based screening tool to predict clinical immunogenicity of biologicsNicole L Jarvi, Sathy V Balu-Iyer
Thrombosis and Haemostasis|April 9, 2011
Phospholipid binding lowers immunogenicity of human recombinant factor VIII in von Willebrand factor knockout miceD S Pisal, S V Balu-Iyer
International Journal of Pharmaceutics|July 8, 2018
Subcutaneous administration of Lyso-phosphatidylserine nanoparticles induces immunological tolerance towards Factor VIII in a Hemophilia A mouse modelFiona Y Glassman, Sathy V Balu-Iyer
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|January 10, 2026
Immunogenicity of Gene and Cell TherapiesKirk Hofman, Priyanka Jangied, Sathy V Balu-Iyer
Texas Heart Institute Journal|March 1, 1986
Stress test evaluation of patients with poor left ventricular function before and after coronary artery bypass surgeryV Balu, L Szmedra, D Dean, et al.
Journal of Pharmaceutical Sciences|June 4, 2015
Exposure of FVIII in the Presence of Phosphatidyl Serine Reduces Generation of Memory B-Cells and Induces Regulatory T-Cell-Mediated Hyporesponsiveness in Hemophilia A MiceRadha Ramakrishnan, Andrew Davidowitz, Sathy V Balu-Iyer
Texas Heart Institute Journal|January 1, 1988
Long-term survival of patients with low ejection fraction: surgical versus medical managementV Balu, L Szmedra, D Dean, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|December 3, 2014
Intravenous administration of Factor VIII-O-Phospho-L-Serine (OPLS) complex reduces immunogenicity and preserves pharmacokinetics of the therapeutic proteinPuneet Gaitonde, Vivek S Purohit, Sathy V Balu-Iyer
Journal of Pharmaceutical Sciences|October 1, 2014
O-phospho-l-serine mediates hyporesponsiveness toward FVIII in hemophilia A-murine model by inducing tolerogenic properties in dendritic cellsAnas M Fathallah, Radha Ramakrishnan, Sathy V Balu-Iyer
Proteomes|March 27, 2026
Proteomic Insights into the Immune and Sex-Specific Proteins in the Skin Mucus of Barramundi (<i>Lates calcarifer</i>)Varsha V Balu, Dean R Jerry, Andreas L Lopata
Pageof 8

Showing results (11-20 of 76) with videos related to

Sort By:
Pageof 8
Communications Medicine|December 8, 2023
A mechanistic marker-based screening tool to predict clinical immunogenicity of biologicsNicole L Jarvi, Sathy V Balu-Iyer
Thrombosis and Haemostasis|April 9, 2011
Phospholipid binding lowers immunogenicity of human recombinant factor VIII in von Willebrand factor knockout miceD S Pisal, S V Balu-Iyer
International Journal of Pharmaceutics|July 8, 2018
Subcutaneous administration of Lyso-phosphatidylserine nanoparticles induces immunological tolerance towards Factor VIII in a Hemophilia A mouse modelFiona Y Glassman, Sathy V Balu-Iyer
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|January 10, 2026
Immunogenicity of Gene and Cell TherapiesKirk Hofman, Priyanka Jangied, Sathy V Balu-Iyer
Texas Heart Institute Journal|March 1, 1986
Stress test evaluation of patients with poor left ventricular function before and after coronary artery bypass surgeryV Balu, L Szmedra, D Dean, et al.
Journal of Pharmaceutical Sciences|June 4, 2015
Exposure of FVIII in the Presence of Phosphatidyl Serine Reduces Generation of Memory B-Cells and Induces Regulatory T-Cell-Mediated Hyporesponsiveness in Hemophilia A MiceRadha Ramakrishnan, Andrew Davidowitz, Sathy V Balu-Iyer
Texas Heart Institute Journal|January 1, 1988
Long-term survival of patients with low ejection fraction: surgical versus medical managementV Balu, L Szmedra, D Dean, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|December 3, 2014
Intravenous administration of Factor VIII-O-Phospho-L-Serine (OPLS) complex reduces immunogenicity and preserves pharmacokinetics of the therapeutic proteinPuneet Gaitonde, Vivek S Purohit, Sathy V Balu-Iyer
Journal of Pharmaceutical Sciences|October 1, 2014
O-phospho-l-serine mediates hyporesponsiveness toward FVIII in hemophilia A-murine model by inducing tolerogenic properties in dendritic cellsAnas M Fathallah, Radha Ramakrishnan, Sathy V Balu-Iyer
Proteomes|March 27, 2026
Proteomic Insights into the Immune and Sex-Specific Proteins in the Skin Mucus of Barramundi (<i>Lates calcarifer</i>)Varsha V Balu, Dean R Jerry, Andreas L Lopata
Pageof 8